Invivyd (IVVD) Competitors $0.41 -0.03 (-7.49%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends IVVD vs. PROC, IKT, HURA, NLTX, ZNTL, PRQR, CRDF, CYBN, SLN, and CGENShould you be buying Invivyd stock or one of its competitors? The main competitors of Invivyd include Procaps Group (PROC), Inhibikase Therapeutics (IKT), TuHURA Biosciences (HURA), Neoleukin Therapeutics (NLTX), Zentalis Pharmaceuticals (ZNTL), ProQR Therapeutics (PRQR), Cardiff Oncology (CRDF), Cybin (CYBN), Silence Therapeutics (SLN), and Compugen (CGEN). These companies are all part of the "pharmaceutical products" industry. Invivyd vs. Procaps Group Inhibikase Therapeutics TuHURA Biosciences Neoleukin Therapeutics Zentalis Pharmaceuticals ProQR Therapeutics Cardiff Oncology Cybin Silence Therapeutics Compugen Invivyd (NASDAQ:IVVD) and Procaps Group (NASDAQ:PROC) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, community ranking, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations. Which has more risk & volatility, IVVD or PROC? Invivyd has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500. Comparatively, Procaps Group has a beta of -0.03, suggesting that its stock price is 103% less volatile than the S&P 500. Is IVVD or PROC more profitable? Procaps Group's return on equity of 0.00% beat Invivyd's return on equity.Company Net Margins Return on Equity Return on Assets InvivydN/A -155.33% -114.88% Procaps Group N/A N/A N/A Does the MarketBeat Community believe in IVVD or PROC? Invivyd received 13 more outperform votes than Procaps Group when rated by MarketBeat users. Likewise, 80.00% of users gave Invivyd an outperform vote while only 37.50% of users gave Procaps Group an outperform vote. CompanyUnderperformOutperformInvivydOutperform Votes1680.00% Underperform Votes420.00% Procaps GroupOutperform Votes337.50% Underperform Votes562.50% Do analysts rate IVVD or PROC? Invivyd currently has a consensus price target of $7.89, suggesting a potential upside of 1,840.82%. Given Invivyd's stronger consensus rating and higher probable upside, equities research analysts clearly believe Invivyd is more favorable than Procaps Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invivyd 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Procaps Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has preferable valuation and earnings, IVVD or PROC? Procaps Group has higher revenue and earnings than Invivyd. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInvivydN/AN/A-$198.64M-$1.96-0.21Procaps Group$409.92MN/A$42.54MN/AN/A Does the media refer more to IVVD or PROC? In the previous week, Invivyd and Invivyd both had 2 articles in the media. Procaps Group's average media sentiment score of 1.26 beat Invivyd's score of -0.27 indicating that Procaps Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Invivyd 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Procaps Group 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of IVVD or PROC? 70.4% of Invivyd shares are held by institutional investors. 17.9% of Invivyd shares are held by company insiders. Comparatively, 19.9% of Procaps Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryInvivyd beats Procaps Group on 8 of the 14 factors compared between the two stocks. Get Invivyd News Delivered to You Automatically Sign up to receive the latest news and ratings for IVVD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IVVD vs. The Competition Export to ExcelMetricInvivydBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$54.07M$2.96B$5.23B$8.96BDividend YieldN/A1.94%5.13%4.04%P/E Ratio-0.2141.4783.3616.84Price / SalesN/A265.171,257.9179.09Price / CashN/A192.9043.8235.97Price / Book0.253.965.324.79Net Income-$198.64M-$41.02M$122.78M$224.99M7 Day Performance-10.09%-1.76%-0.20%1.50%1 Month Performance-8.59%0.51%3.71%4.68%1 Year Performance-90.85%-1.71%27.30%20.92% Invivyd Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IVVDInvivyd3.0557 of 5 stars$0.41-7.5%$7.89+1,840.8%-90.1%$54.07MN/A-0.21100Short Interest ↑PROCProcaps GroupN/A$1.68+5.0%N/A-60.0%$189.54M$414.10M3.235,500Short Interest ↓News CoveragePositive NewsGap UpIKTInhibikase Therapeutics1.6233 of 5 stars$2.82-4.4%$6.50+130.5%+64.8%$189.48M$260,000.00-1.066HURATuHURA BiosciencesN/A$4.45-8.2%$13.00+192.1%N/A$188.17MN/A0.00N/APositive NewsNLTXNeoleukin TherapeuticsN/A$19.58-8.9%N/A-41.5%$184.01MN/A-6.3090News CoverageHigh Trading VolumeZNTLZentalis Pharmaceuticals2.8628 of 5 stars$2.55-7.3%$10.00+292.2%-83.3%$181.73M$40.56M-1.02160Short Interest ↓News CoveragePRQRProQR Therapeutics2.7546 of 5 stars$2.19-9.5%$8.83+303.3%-16.8%$178.88M$17.88M-6.84180Short Interest ↑CRDFCardiff Oncology2.9189 of 5 stars$3.46-4.2%$10.33+198.7%+134.7%$176.92M$688,000.00-3.6820Positive NewsCYBNCybin2.6895 of 5 stars$8.84-0.6%$138.00+1,461.1%N/A$176.73MN/A-1.3350News CoveragePositive NewsSLNSilence Therapeutics2.7279 of 5 stars$5.89-1.7%$57.20+871.1%-71.7%$176.28M$16.25M-3.75100News CoverageCGENCompugen2.4162 of 5 stars$1.98+20.4%$4.00+102.5%+19.0%$176.24M$59.85M98.7570High Trading Volume Related Companies and Tools Related Companies PROC Competitors IKT Competitors HURA Competitors NLTX Competitors ZNTL Competitors PRQR Competitors CRDF Competitors CYBN Competitors SLN Competitors CGEN Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IVVD) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon's "Final Move" Could Send This Stock SoaringWhenever Elon Musk starts a new venture... Early investors get the opportunity to become millionaires... ...Behind the Markets | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invivyd, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invivyd With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
